Insight Molecular Diagnostics Inc. — Delisting Announcement 2021

Mar 5, 2021

25 1 form25.htm

Field: Rule-Page

Field: /Rule-Page

| UNITED
STATES | OMB
APPROVAL |
| --- | --- |
| SECURITIES
AND EXCHANGE COMMISSION | OMB Number:
3235-0080 |
| Washington,
D. C. 20549 | Expires: March
31, 2021 |
| | Estimated
average burden |
| FORM
25 | hours per
response 1.00 |

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 1-37648

| OncoCyte Corporation,
NYSE American |
| --- |
| (Exact
name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |

| 15 Cushing, Irvine, California 92618, (949)
409-7600 |
| --- |
| (Address,
including zip code, and telephone number, including area code, of Issuer’s principal executive offices) |

Common Stock, no par value
(Description
of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

| [ ] | 17
CFR 240.12d2-2(a)(1) |
| --- | --- |
| [ ] | 17
CFR 240.12d2-2(a)(2) |
| [ ] | 17
CFR 240.12d2-2(a)(3) |
| [ ] | 17
CFR 240.12d2-2(a)(4) |

[ ] Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1

[X] Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, OncoCyte Corporation certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

March 5, 2021	/s/ Mitchell Levine	Chief Financial Officer
Date	Name:
Mitchell Levine	Title

Field: Rule-Page

Field: /Rule-Page

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

SEC 1654 (03-06) Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1; Options: Last

Field: /Page